Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Conference for NASH Summit Europe 2017
September 25, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced Peter G. Traber, M.D., the...
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
June 13, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
Galectin Therapeutics Reports Third Quarter 2016 Financial Results and Provides Business Update
November 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis
September 14, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...
Raptor Pharmaceutical Receives FDA Approval of Expanded Label for PROCYSBI(R) to Treat Children Aged 2-6 Years With Nephropathic Cystinosis
August 17, 2015 07:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 17, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced that the U.S. Food and Drug Administration (FDA) approved the expanded use of PROCYSBI®...
Raptor Pharmaceutical Announces Management Changes
July 15, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 15, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced the appointment of Ashley Gould, J.D. as its Senior Vice President, General Counsel and...
Raptor Pharmaceutical to Participate in Upcoming Investor Conferences
May 28, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 28, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that Julie Anne Smith, President and Chief Executive Officer, will present at the following...
Raptor Pharmaceutical to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference
May 06, 2015 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 6, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will present at the following conference:
Julie Anne Smith, President and Chief...
Raptor Pharmaceutical Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares
April 08, 2015 12:13 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 8, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company focused on developing and commercializing transformative treatments for people...
Intercept Pharmaceuticals Announces 2014 Financial Results
March 02, 2015 06:00 ET
|
Intercept Pharmaceuticals, Inc.
NEW YORK, March 2, 2015 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of...